Eurofins-Cerep SA
PAR:ALECR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Eurofins-Cerep SA
Eurofins-Cerep SA
Cash from Financing Activities
Eurofins-Cerep SA
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eurofins-Cerep SA
PAR:ALECR
|
Cash from Financing Activities
-€5.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-17%
|
|
|
Sartorius Stedim Biotech SA
PAR:DIM
|
Cash from Financing Activities
€2.3B
|
CAGR 3-Years
447%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pcas SA
PAR:PCA
|
Cash from Financing Activities
-€23.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-130%
|
CAGR 10-Years
-35%
|
|
Eurofins-Cerep SA
Glance View
Eurofins-Cerep SA engages in providing preclinical drug research services. The company is headquartered in Celle-Levescault, Nouvelle-Aquitaine and currently employs 211 full-time employees. The company went IPO on 2010-03-19. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The firm then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. In December 2013, it sold Cerep Inc, its American subsidiary, to Eurofins-Panlabs Inc, part of the Eurofins Scientific SE group.
See Also
What is Eurofins-Cerep SA's Cash from Financing Activities?
Cash from Financing Activities
-5.7m
EUR
Based on the financial report for Jun 30, 2023, Eurofins-Cerep SA's Cash from Financing Activities amounts to -5.7m EUR.
What is Eurofins-Cerep SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-17%
The average annual Cash from Financing Activities growth rates for Eurofins-Cerep SA have been 11% over the past three years , 4% over the past five years , and -17% over the past ten years .
You don't have any saved screeners yet
